157 related articles for article (PubMed ID: 32934224)
21. Structure and cancer immunotherapy of the B7 family member B7x.
Jeon H; Vigdorovich V; Garrett-Thomson SC; Janakiram M; Ramagopal UA; Abadi YM; Lee JS; Scandiuzzi L; Ohaegbulam KC; Chinai JM; Zhao R; Yao Y; Mao Y; Sparano JA; Almo SC; Zang X
Cell Rep; 2014 Nov; 9(3):1089-98. PubMed ID: 25437562
[TBL] [Abstract][Full Text] [Related]
22. MS-275 inhibits aroclor 1254-induced SH-SY5Y neuronal cell toxicity by preventing the formation of the HDAC3/REST complex on the synapsin-1 promoter.
Formisano L; Guida N; Laudati G; Mascolo L; Di Renzo G; Canzoniero LM
J Pharmacol Exp Ther; 2015 Feb; 352(2):236-43. PubMed ID: 25467131
[TBL] [Abstract][Full Text] [Related]
23. Histone deacetylase inhibitor induction of P-glycoprotein transcription requires both histone deacetylase 1 dissociation and recruitment of CAAT/enhancer binding protein beta and pCAF to the promoter region.
Kim SN; Kim NH; Lee W; Seo DW; Kim YK
Mol Cancer Res; 2009 May; 7(5):735-44. PubMed ID: 19435809
[TBL] [Abstract][Full Text] [Related]
24. Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin.
Hayashi A; Horiuchi A; Kikuchi N; Hayashi T; Fuseya C; Suzuki A; Konishi I; Shiozawa T
Int J Cancer; 2010 Sep; 127(6):1332-46. PubMed ID: 20049841
[TBL] [Abstract][Full Text] [Related]
25. HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti-PD-L1 Therapy.
Deng S; Hu Q; Zhang H; Yang F; Peng C; Huang C
Mol Cancer Ther; 2019 May; 18(5):900-908. PubMed ID: 30824609
[TBL] [Abstract][Full Text] [Related]
26. Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
Li X; Zhang Y; Jiang Y; Wu J; Inks ES; Chou CJ; Gao S; Hou J; Ding Q; Li J; Wang X; Huang Y; Xu W
Eur J Med Chem; 2017 Jul; 134():185-206. PubMed ID: 28415009
[TBL] [Abstract][Full Text] [Related]
27. Histone deacetylase inhibitors induce attenuation of Wnt signaling and TCF7L2 depletion in colorectal carcinoma cells.
Götze S; Coersmeyer M; Müller O; Sievers S
Int J Oncol; 2014 Oct; 45(4):1715-23. PubMed ID: 25050608
[TBL] [Abstract][Full Text] [Related]
28. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
Kim JS; Lee SC; Min HY; Park KH; Hyun SY; Kwon SJ; Choi SP; Kim WY; Lee HJ; Lee HY
Cancer Lett; 2015 Jun; 361(2):197-206. PubMed ID: 25721083
[TBL] [Abstract][Full Text] [Related]
29. A novel class I histone deacetylase inhibitor, I-7ab, induces apoptosis and arrests cell cycle progression in human colorectal cancer cells.
Yang L; Liang Q; Shen K; Ma L; An N; Deng W; Fei Z; Liu J
Biomed Pharmacother; 2015 Apr; 71():70-8. PubMed ID: 25960218
[TBL] [Abstract][Full Text] [Related]
30. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.
Fabian J; Lodrini M; Oehme I; Schier MC; Thole TM; Hielscher T; Kopp-Schneider A; Opitz L; Capper D; von Deimling A; Wiegand I; Milde T; Mahlknecht U; Westermann F; Popanda O; Roels F; Hero B; Berthold F; Fischer M; Kulozik AE; Witt O; Deubzer HE
Cancer Res; 2014 May; 74(9):2604-16. PubMed ID: 24419085
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
[TBL] [Abstract][Full Text] [Related]
32. HDAC3 mediates smoking-induced pancreatic cancer.
Edderkaoui M; Xu S; Chheda C; Morvaridi S; Hu RW; Grippo PJ; Mascariñas E; Principe DR; Knudsen B; Xue J; Habtezion A; Uyeminami D; Pinkerton KE; Pandol SJ
Oncotarget; 2016 Feb; 7(7):7747-60. PubMed ID: 26745602
[TBL] [Abstract][Full Text] [Related]
33. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
[TBL] [Abstract][Full Text] [Related]
34. A novel class I HDAC inhibitor, MPT0G030, induces cell apoptosis and differentiation in human colorectal cancer cells via HDAC1/PKCδ and E-cadherin.
Wang LT; Liou JP; Li YH; Liu YM; Pan SL; Teng CM
Oncotarget; 2014 Jul; 5(14):5651-62. PubMed ID: 25015091
[TBL] [Abstract][Full Text] [Related]
35. Endocrine resistant breast cancer cells with loss of ERα expression retain proliferative ability by reducing caspase7-mediated HDAC3 cleavage.
Yu S; Gong X; Ma Z; Zhang M; Huang L; Zhang J; Zhao S; Zhu T; Yu Z; Chen L
Cell Oncol (Dordr); 2020 Feb; 43(1):65-80. PubMed ID: 31701491
[TBL] [Abstract][Full Text] [Related]
36. Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells.
Hoffmann MJ; Meneceur S; Hommel K; Schulz WA; Niegisch G
Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33670166
[TBL] [Abstract][Full Text] [Related]
37. Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.
Matthews GM; Mehdipour P; Cluse LA; Falkenberg KJ; Wang E; Roth M; Santoro F; Vidacs E; Stanley K; House CM; Rusche JR; Vakoc CR; Zuber J; Minucci S; Johnstone RW
Blood; 2015 Nov; 126(21):2392-403. PubMed ID: 26447190
[TBL] [Abstract][Full Text] [Related]
38. Pan-histone deacetylase inhibitor panobinostat sensitizes gastric cancer cells to anthracyclines via induction of CITED2.
Regel I; Merkl L; Friedrich T; Burgermeister E; Zimmermann W; Einwächter H; Herrmann K; Langer R; Röcken C; Hofheinz R; Schmid R; Ebert MP
Gastroenterology; 2012 Jul; 143(1):99-109.e10. PubMed ID: 22465428
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of histone deacetylase reduces transcription of NADPH oxidases and ROS production and ameliorates pulmonary arterial hypertension.
Chen F; Li X; Aquadro E; Haigh S; Zhou J; Stepp DW; Weintraub NL; Barman SA; Fulton DJR
Free Radic Biol Med; 2016 Oct; 99():167-178. PubMed ID: 27498117
[TBL] [Abstract][Full Text] [Related]
40. Modulation of STAT1-Driven Transcriptional Activity by Histone Deacetylases.
Owusu BY; Klampfer L
Methods Mol Biol; 2017; 1510():277-285. PubMed ID: 27761828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
